BLASUBCUTANEOUSINJECTABLE1 Generic Approved
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TYENNE (tocilizumab-aazg) by Fresenius Kabi is interleukin 6 receptor antagonists [moa]. First approved in 2025.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYENNE (tocilizumab-aazg) is a monoclonal antibody that antagonizes the interleukin-6 receptor, modulating immune response in inflammatory and autoimmune conditions. This subcutaneous injectable represents a biosimilar or novel formulation within the established IL-6 inhibitor class. The drug addresses unmet needs in patient populations requiring IL-6 pathway modulation.
Growth
Early-stage product in growth phase signals active team expansion and opportunity for foundational commercial role building.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TYENNE is a newly approved growth-stage product with minimal linked job data, creating early-career opportunity to build franchise from foundation. Working on this product offers exposure to biologic commercialization, competitive differentiation strategy, and potential expansion into multiple indications.
Brand Manager
Worked on TYENNE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.